Cargando…

Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III/IV Non-Small Cell Lung Cancer: A PRISMA-Compliant Meta-Analysis

Objective: Kanglaite(KLT), a type of Chinese medicine preparation, is considered as an adjuvant therapeutic option for malignant cancer treatment. This study aimed to systematically investigate the efficacy and safety of the combination of KLT and epidermal growth factor receptor-tyrosine kinase inh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Fanming, Wang, Chaoran, Li, Xiaojiang, Jia, Yingjie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473705/ https://www.ncbi.nlm.nih.gov/pubmed/34588988 http://dx.doi.org/10.3389/fphar.2021.739843

Ejemplares similares

Efficacy and safety of Kanglaite injection combined with radiochemotherapy in the treatment of advanced pancreatic cancer: A PRISMA-compliant meta-analysis
por: Liu, Jianling, et al.
Publicado: (2019)

The clinical efficacy and safety of kanglaite adjuvant therapy in the treatment of advanced hepatocellular carcinoma: A PRISMA-compliant meta-analysis
por: Liu, Jingjing, et al.
Publicado: (2019)

The Current Application and Future Prospects of Astragalus Polysaccharide Combined With Cancer Immunotherapy: A Review
por: Kong, Fanming, et al.
Publicado: (2021)

Kanglaite (Coix Seed Extract) as Adjunctive Therapy in Cancer: Evidence Mapping Overview Based on Systematic Reviews With Meta-Analyses
por: Lu, Cuncun, et al.
Publicado: (2022)

The Role of Epidermal Growth Factor Receptor Family of Receptor Tyrosine Kinases in Mediating Diabetes-Induced Cardiovascular Complications
por: Shraim, Bara A., et al.
Publicado: (2021)

Efficacy and safety of bevacizumab in patients with malignant melanoma: a systematic review and PRISMA-compliant meta-analysis of randomized controlled trials and non-comparative clinical studies
por: Han, Xiao, et al.
Publicado: (2023)

Evaluation of Efficacy and Safety for Kanglaite Injection in the Control of the Malignant Pleural Effusions via Thoracic Perfusion: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Zhu, Guanghui, et al.
Publicado: (2021)

Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
por: Zhang, Wei, et al.
Publicado: (2018)

Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors
por: Centanni, Maddalena, et al.
Publicado: (2020)

Predicting individual-specific cardiotoxicity responses induced by tyrosine kinase inhibitors
por: Shim, Jaehee V., et al.
Publicado: (2023)

Analysis of intracellular tyrosine phosphorylation in circulating neutrophils as a rapid assay for the in vivo effect of oral tyrosine kinase inhibitors
por: Futosi, Krisztina, et al.
Publicado: (2023)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non–small-cell lung cancer: A PRISMA-compliant meta-analysis
por: Lv, Wen-wen, et al.
Publicado: (2019)

Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis
por: Paech, Franziska, et al.
Publicado: (2017)

Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential
por: Rivera-Torres, José, et al.
Publicado: (2019)

The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae
por: Wang, Kun, et al.
Publicado: (2021)

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
por: Singh, Desh Deepak, et al.
Publicado: (2022)

Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity
por: Chen, Xiaojie, et al.
Publicado: (2022)

Inhibition of Spleen Tyrosine Kinase Restores Glucocorticoid Sensitivity to Improve Steroid-Resistant Asthma
por: Liu, Qian, et al.
Publicado: (2022)

Unraveling the Function of Lemur Tyrosine Kinase 2 Network
por: Cruz, Daniel F., et al.
Publicado: (2019)

Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap
por: Piris-Villaespesa, Miguel, et al.
Publicado: (2020)

Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study
por: Liu, Yihan, et al.
Publicado: (2022)

Role of Bruton’s Tyrosine Kinase in Stage III Colorectal Cancer
por: Basile, Debora, et al.
Publicado: (2019)

Value of preoperative staging of endometrial carcinoma with contrast-enhanced ultrasonography: A PRISMA compliant meta-analysis
por: Tong, Xiaozhen, et al.
Publicado: (2021)

Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients
por: Liu, Yang, et al.
Publicado: (2023)

Antitumor effect of Kanglaite® injection in human pancreatic cancer xenografts
por: Liu, Ying, et al.
Publicado: (2014)

Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection
por: Climent, Núria, et al.
Publicado: (2019)

Ultrasound is helpful to differentiate Bethesda class III thyroid nodules: A PRISMA-compliant systematic review and meta-analysis
por: Gao, Lu-Ying, et al.
Publicado: (2017)

The efficacy of acupuncture with Lingguibafa acupoint selection in the treatment of insomnia: A PRISMA-compliant meta-analysis
por: Ji, Haiyang, et al.
Publicado: (2022)

Cutaneous fistulization of the hydatid disease: A PRISMA-compliant systematic review
por: Bahce, Zeynep Sener, et al.
Publicado: (2016)

Prevalence of depression in myocardial infarction: A PRISMA-compliant meta-analysis
por: Feng, Limin, et al.
Publicado: (2019)

Pediatric plexiform fibromyxoma: A PRISMA-compliant systematic literature review
por: Fukazawa, Mitsuharu, et al.
Publicado: (2019)

Chemerin as Potential Biomarker in Pediatric Diseases: A PRISMA-Compliant Study
por: Zdanowicz, Katarzyna, et al.
Publicado: (2022)

Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
por: Kaehler, Meike, et al.
Publicado: (2021)

Novel biomarkers used for early diagnosis and tyrosine kinase inhibitors as targeted therapies in colorectal cancer
por: Jiang, Huafeng, et al.
Publicado: (2023)

Compound 15c, a Novel Dual Inhibitor of EGFR(L858R/T790M) and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers
por: Chen, Gaozhi, et al.
Publicado: (2020)

Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1
por: Uddin, Muhammad Erfan, et al.
Publicado: (2021)

Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
por: Sudhesh Dev, Sareshma, et al.
Publicado: (2021)

Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging
por: Qawasmi, Israa, et al.
Publicado: (2014)

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
por: Lu, Ziwen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_muc99uvq79vn88kb37sc61up8l